Literature DB >> 12551862

C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis.

Sridevi Devaraj1, Dan Yan Xu, Ishwarlal Jialal.   

Abstract

BACKGROUND: Inflammation plays a pivotal role in atherosclerosis. In addition to being a risk marker for cardiovascular disease, much recent data suggest that C-reactive protein (CRP) promotes atherogenesis via effects on monocytes and endothelial cells. The metabolic syndrome is associated with significantly elevated levels of CRP. Plasminogen activator inhibitor-1 (PAI-1), a marker of atherothrombosis, is also elevated in the metabolic syndrome and in diabetes, and endothelial cells are the major source of PAI-1. However, there are no studies examining the effect of CRP on PAI-1 in human aortic endothelial cells (HAECs). METHODS AND
RESULTS: Incubation of HAECs with CRP results in a time- and dose-dependent increase in secreted PAI-1 antigen, PAI-1 activity, intracellular PAI-1 protein, and PAI-1 mRNA. CRP stabilizes PAI-1 mRNA. Inhibitors of endothelial NO synthase, blocking antibodies to interleukin-6 and an endothelin-1 receptor blocker, fail to attenuate the effect of CRP on PAI-1. CRP additionally increased PAI-1 under hyperglycemic conditions.
CONCLUSIONS: This study makes the novel observation that CRP induces PAI-1 expression and activity in HAECs and thus has implications for both the metabolic syndrome and atherothrombosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12551862     DOI: 10.1161/01.cir.0000052617.91920.fd

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  131 in total

1.  Evidence for an association between type 1 diabetes and premature carotid atherosclerosis in childhood.

Authors:  M E Atabek; O Pirgon; S Kurtoglu; H Imamoglu
Journal:  Pediatr Cardiol       Date:  2006 Jul-Aug       Impact factor: 1.655

Review 2.  C-reactive protein and risk of cardiovascular disease: evidence and clinical application.

Authors:  Paul M Ridker; Shari S Bassuk; Peter P Toth
Journal:  Curr Atheroscler Rep       Date:  2003-09       Impact factor: 5.113

Review 3.  Inflammatory and oxidative markers in atherosclerosis: relationship to outcome.

Authors:  Mehdi H Shishehbor; Stanley L Hazen
Journal:  Curr Atheroscler Rep       Date:  2004-05       Impact factor: 5.113

4.  Autoantibodies and thrombophilia in RA: TNFalpha and TNFalpha blockers.

Authors:  G F Ferraccioli; E Gremese
Journal:  Ann Rheum Dis       Date:  2004-03-17       Impact factor: 19.103

Review 5.  Inflammation and atherosclerosis.

Authors:  Mehdi H Shishehbor; Deepak L Bhatt
Journal:  Curr Atheroscler Rep       Date:  2004-03       Impact factor: 5.113

Review 6.  Do statins offer therapeutic potential in inflammatory arthritis?

Authors:  I B McInnes; D W McCarey; N Sattar
Journal:  Ann Rheum Dis       Date:  2004-12       Impact factor: 19.103

Review 7.  Coagulability in obstructive sleep apnea.

Authors:  Christina Liak; M Fitzpatrick
Journal:  Can Respir J       Date:  2011 Nov-Dec       Impact factor: 2.409

Review 8.  Impact of genetic and environmental factors on hsCRP concentrations and response to therapeutic agents.

Authors:  Jian Shen; Jose M Ordovas
Journal:  Clin Chem       Date:  2008-12-12       Impact factor: 8.327

Review 9.  Blood-borne biomarkers and bioindicators for linking exposure to health effects in environmental health science.

Authors:  M Ariel Geer Wallace; Tzipporah M Kormos; Joachim D Pleil
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2016-10-19       Impact factor: 6.393

10.  Plasminogen activator inhibitor-1 removal using dextran sulphate columns. Evidence of PAI-1 homeostasis.

Authors:  Vincent M G Maher; Yuri Kitano; Clare Neuwirth; Graham J Davies; Attilio Maseri; Gilbert R Thompson; Felicita Andreotti
Journal:  J Thromb Thrombolysis       Date:  2008-07-30       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.